Evaluation of the effects of anakinra treatment on clinic and laboratory results in patients with COVID-19.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Northern Clinics of Istanbul Pub Date : 2023-04-19 eCollection Date: 2023-01-01 DOI:10.14744/nci.2022.01047
Ozge Siyer, Berrin Aksakal, Sema Basat
{"title":"Evaluation of the effects of anakinra treatment on clinic and laboratory results in patients with COVID-19.","authors":"Ozge Siyer,&nbsp;Berrin Aksakal,&nbsp;Sema Basat","doi":"10.14744/nci.2022.01047","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Some anti-cytokine treatments are being used to control the hyperinflammatory condition defined as cytokine storm that develops during COVID-19 infection. In this study, we aim to investigate the effects of anakinra, an IL-1 antagonist, on the clinical status and laboratory values of hospitalized patients with the COVID-19 infection. The aim of the study was to investigate the effects of anakinra, an IL-1 antagonist, on the clinical and laboratory results of hospitalized patients with COVID-19 infection.</p><p><strong>Methods: </strong>This study was planned as a retrospective study. The age, gender, and current comorbidities of a total of 66 patients who were treated with anakinra for COVID-19 infection from November 2020 to January 2021 were analyzed. The amount of oxygen demand (L/s), the type of oxygen supplementation, oxygen saturation, radiological findings, WBC count, lymphocyte count, neutrophil count, C-reactive protein, LDH, ferritin, fibrinogen, D-dimer levels were monitored before the treatment, and after the anakinra treatment, newly gathered results were compared. Patients' hospitalization period, oxygen need, and their clinical status at discharge were evaluated. The effects of early anakinra treatment (9 days before and after the onset of symptoms) on the prognosis were evaluated. SPSS version 21.0 provided by IBM Company in the USA, Chicago, IL was used for statistical analysis and p<0.05 was considered significant.</p><p><strong>Results: </strong>Sixty-six patients were included in the study. There was no significant gender difference in the prognosis of the patients. There was a significant difference in the statistical deterioration in patients with comorbidities (p=0.004). Patients who started the anakinra treatment at an early stage developed less need for intensive care and low mortality ratios (p=0.019). There were significant improvements on the levels of WBC (p=0.045), neutrophils (p=0.016), lymphocyte (p=0.001), LDH (p=0.005), ferritin (p=0.02), and fibrinogen (p=0.01) after the administration of anakinra therapy.</p><p><strong>Conclusion: </strong>We found that earlier and appropriate use of anakinra therapy in COVID-19 patients with the signs of macrophage activation syndrome reduces the need for oxygen support in patients and contributes to improvement in laboratory results and radiological findings, and most importantly reduces the need for intensive care.</p>","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":"10 2","pages":"189-196"},"PeriodicalIF":0.9000,"publicationDate":"2023-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/1b/NCI-10-189.PMC10170373.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2022.01047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: Some anti-cytokine treatments are being used to control the hyperinflammatory condition defined as cytokine storm that develops during COVID-19 infection. In this study, we aim to investigate the effects of anakinra, an IL-1 antagonist, on the clinical status and laboratory values of hospitalized patients with the COVID-19 infection. The aim of the study was to investigate the effects of anakinra, an IL-1 antagonist, on the clinical and laboratory results of hospitalized patients with COVID-19 infection.

Methods: This study was planned as a retrospective study. The age, gender, and current comorbidities of a total of 66 patients who were treated with anakinra for COVID-19 infection from November 2020 to January 2021 were analyzed. The amount of oxygen demand (L/s), the type of oxygen supplementation, oxygen saturation, radiological findings, WBC count, lymphocyte count, neutrophil count, C-reactive protein, LDH, ferritin, fibrinogen, D-dimer levels were monitored before the treatment, and after the anakinra treatment, newly gathered results were compared. Patients' hospitalization period, oxygen need, and their clinical status at discharge were evaluated. The effects of early anakinra treatment (9 days before and after the onset of symptoms) on the prognosis were evaluated. SPSS version 21.0 provided by IBM Company in the USA, Chicago, IL was used for statistical analysis and p<0.05 was considered significant.

Results: Sixty-six patients were included in the study. There was no significant gender difference in the prognosis of the patients. There was a significant difference in the statistical deterioration in patients with comorbidities (p=0.004). Patients who started the anakinra treatment at an early stage developed less need for intensive care and low mortality ratios (p=0.019). There were significant improvements on the levels of WBC (p=0.045), neutrophils (p=0.016), lymphocyte (p=0.001), LDH (p=0.005), ferritin (p=0.02), and fibrinogen (p=0.01) after the administration of anakinra therapy.

Conclusion: We found that earlier and appropriate use of anakinra therapy in COVID-19 patients with the signs of macrophage activation syndrome reduces the need for oxygen support in patients and contributes to improvement in laboratory results and radiological findings, and most importantly reduces the need for intensive care.

Abstract Image

Abstract Image

Abstract Image

新冠肺炎患者anakinra治疗对临床和实验室结果的影响评估。
目的:一些抗细胞因子治疗正在被用于控制新冠肺炎感染期间发生的高炎症状态,即细胞因子风暴。在这项研究中,我们的目的是研究白细胞介素1拮抗剂anakinra对新冠肺炎感染住院患者的临床状况和实验室价值的影响。本研究的目的是研究IL-1拮抗剂anakinra对新冠肺炎感染住院患者临床和实验室结果的影响。方法:本研究为回顾性研究。分析了2020年11月至2021年1月期间共66名因新冠肺炎感染接受安纳金治疗的患者的年龄、性别和当前合并症。治疗前监测需氧量(L/s)、补氧类型、血氧饱和度、放射学检查结果、WBC计数、淋巴细胞计数、中性粒细胞计数、C反应蛋白、LDH、铁蛋白、纤维蛋白原、D-二聚体水平,治疗后比较新收集的结果。评估患者的住院时间、氧气需求和出院时的临床状况。评估早期anakinra治疗(症状出现前后9天)对预后的影响。采用美国芝加哥IBM公司提供的SPSS 21.0版进行统计分析。患者的预后没有显著的性别差异。合并症患者的统计恶化存在显著差异(p=0.004)。早期开始安纳金拉治疗的患者对重症监护的需求减少,死亡率较低(p=0.019)。WBC(p=0.045)、中性粒细胞(p=0.016)、淋巴细胞(p=0.001)、LDH(p=0.005)、铁蛋白(p=0.02),和纤维蛋白原(p=0.01)。结论:我们发现,在有巨噬细胞活化综合征症状的新冠肺炎患者中,早期适当使用anakinra治疗可以减少患者对氧气支持的需求,有助于改善实验室结果和放射学检查结果,最重要的是减少重症监护的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Northern Clinics of Istanbul
Northern Clinics of Istanbul MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
0.00%
发文量
48
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信